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Abstract: Progressive obstructive lung disease is a characteristic component of cystic fibrosis 
(CF). It is the pulmonary manifestations, including obstruction and endobronchial infection, 
which directly contribute to the premature mortality of patients affected with CF. Due to the 
devastating effects on the pulmonary system, interest abounds in ways to improve antimicro-
bial delivery to the lungs and to impact clinical patient outcomes positively, whilst minimizing 
systemic toxicities. Recently, aztreonam lysine for inhalation solution, a new monobactam 
formulation, was approved by the US Food and Drug Administration for use in a subgroup of 
CF patients with Pseudomonas aeruginosa to improve respiratory symptoms. The purpose of 
this review is to present a summary of relevant pharmacologic, microbiologic, and clinical data 
related to the use of aztreonam lysine for inhalation in patients with CF.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disease characterized by multiple 
organ system dysfunction, primarily affecting the pulmonary and gastrointestinal sys-
tems. The Cystic Fibrosis Foundation reports that approximately 30,000 children and 
adults in the US and 70,000 patients worldwide are afflicted with CF.1 This roughly 
translates into one in every 3500 children in the US being born with CF.1 The incidence 
of CF is greatest among Caucasians and substantially less in other races, affecting one 
in 17,000 blacks and one in 90,000 Asians.1
A hallmark symptom of CF is progressive obstructive lung disease.2–5 Pulmonary 
obstruction contributes to the development of chronic endobronchial infections among 
patients with CF. Complications arising from these infectious processes are associ-
ated with nearly 85% of CF-related mortality.2 Mutations in the CF transmembrane 
conductance regulator protein lead to impairment of Cl-, Na+, and water transport 
in the airways, intestinal epithelia, sweat ducts, and proximal intestine. In the lungs, 
this leads to decreased fluid volume being secreted into the mucus. This results in the 
production of “dehydrated”, thick, and sticky mucus. In turn, this abnormal mucus is 
relatively resistant to ciliary clearance and elimination by cough. The stagnated mucus 
in the airways is prone to bacterial colonization which can lead to infection.3–5 Recur-
rent endobronchial infections and the exaggerated inflammatory response ultimately 
result in progressive endobronchial obstruction and destruction of lung parenchyma, 
  leading to loss of lung function.2–5 Although various bacteria can be cultured from the Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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mucus of patients with CF, approximately 80% of patients 
become chronically infected with Pseudomonas aeruginosa 
by adulthood.1 Chronic colonization and recurrent infection 
with P . aeruginosa, particularly the mucoid phenotype, are 
associated with weight loss, accelerated decline in pulmonary 
function, and premature mortality.6–9
Recognition of the link between colonization and repeated 
infections with P . aeruginosa and deterioration of pulmonary 
function has ushered in an era of improved patient care. 
The standard of care for patients with CF, as it pertains to 
bacterial colonization/infection, focuses on two issues, ie, 
maintaining clear airways and controlling bacterial density. 
Maintenance of clear airways is typically achieved through 
the use of several modalities, including physiotherapy, 
inhaled hypertonic saline, and inhaled dornase alfa.1,2,10 
Additionally, azithromycin may be administered as an adju-
vant therapy to decrease airway inflammation.2 The second 
aspect of care, decreasing bacterial colonization and fighting 
infection, is accomplished via the administration of systemic 
and inhaled antimicrobials.2,11 As a result of these efforts, the 
proportion of patients with preserved lung function and the 
predicted median age of survival have increased since 1985.1 
Unfortunately, despite these gains, CF-related morbidity and 
mortality remain unacceptably high.
Appropriate antibiotic therapy targeted against coloniz-
ing/infecting bacteria, especially P . aeruginosa, is an essen-
tial strategic component of preservation of lung function 
among patients with CF. Regimens consisting of intravenous, 
oral, and/or inhaled formulations of several classes of anti-
biotics including aminoglycosides, β-lactams, polymyxins, 
and fluoroquinolones may have the ability to reduce bacte-
rial densities in sputum. However, evidence linking these 
reductions to sustained improvement or preservation of lung 
function is generally lacking. Owing to the need for long-
term administration to maintain bacterial suppression, drug 
toxicity, patient compliance, and emergence of resistance 
can be significant therapeutic challenges.12 Aerosolized 
administration of antibiotics has been advocated for the man-
agement of endobronchial colonization/infection in patients 
with CF.5 Inhalation of antimicrobials is appealing because it 
can deliver high concentrations of antibiotics directly to the 
airways while minimizing systemic bioavailability and toxic-
ity. Furthermore, delivery of high antibiotic concentrations to 
the lungs may overwhelm the inhibitory effects of purulent 
sputum on antibacterial activity and suppress the emergence 
of resistance.5,13,14 Delivery of antibiotics by inhalation may 
also improve patient adherence to therapies by minimizing 
the need for parenteral administration.
In the setting of CF, aerosolized antibiotics have been 
utilized in three general settings, ie, chronic suppressive 
therapy in patients with stable lung function, treatment for 
colonized patients with suboptimal lung function, and treat-
ment of acute symptomatic pulmonary exacerbations. Until 
recently, tobramycin inhalation solution (TOBI®) was the 
only aerosolized antibiotic approved by the US Food and 
Drug Administration (FDA). Currently, tobramycin inhala-
tion solution is the sole aerosolized antibiotic recognized 
by the Cystic Fibrosis Foundation to improve lung function 
and lung health in patients with CF.2 Tobramycin inhalation 
solution may be considered as maintenance therapy to reduce 
exacerbations of P . aeruginosa infections in CF patients six 
years of age and older with persistent P . aeruginosa positive 
cultures and asymptomatic, mild, or moderate to severe lung 
disease.2,15 Despite this endorsement, lingering concerns 
regarding long-term toxicity, development of resistance, and 
diminished bactericidal activity in the presence of purulent 
sputum persist.13,14,16–18
Interest in the development of aerosolized antibiot-
ics for use among patients with CF remains high. Several 
additional aerosolized antimicrobial formulations are under 
investigation including liposomal, liquid, or dry powder 
formulation of antibiotics, such as a tobramycin-fosfomycin 
combination, amikacin, gentamicin, ciprofloxacin, levo-
floxacin, colistin, azithromycin, and vancomycin.19–23 
Aztreonam for inhalation (Cayston®; Gilead, Foster City, 
CA, USA) was recently approved by the FDA for improve-
ment of respiratory symptoms in CF patients with   
P . aeruginosa who are aged seven years and older with 
forced expiratory volume in one second (FEV1) 25%–75% 
predicted.24 This review was undertaken to summarize and 
present relevant pharmacologic, microbiologic, and clini-
cal data regarding this formulation. Additionally, we have 
attempted to provide insight into pharmacoeconomic and 
quality of life considerations. Data for this review were gath-
ered following a comprehensive literature search of English 
language publications in the PubMed database.
Pharmacology
Aztreonam belongs to the monobactam class of antibiot-
ics. It is a bactericidal agent that exhibits time-dependent 
pharmacodynamics, similar to those of the beta-lactams. 
The mechanism of action of aztreonam is exerted through 
the inhibition of bacterial cell wall synthesis secondary to 
binding to penicillin-binding proteins.24 Aztreonam for injec-
tion (Azactam®; Bristol-Myers Squibb, Princeton, NY, USA) 
is currently available as an intravenous formulation, and is Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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approved for the treatment of complicated and uncomplicated 
urinary tract infections, intra-abdominal infections, skin and 
soft tissue infections, lower respiratory infections, septice-
mia, and gynecologic infections caused by susceptible Gram 
negative organisms.25
The formulation for injection is prepared as an arginine 
salt. It has been reported that this salt may be a substrate for 
the production of nitric oxide in the lung, which may potenti-
ate airway inflammation and induce bronchoconstriction.26,27 
In an attempt to circumvent this problem, a lysine salt of 
aztreonam was developed specifically for inhalational use. 
It should be noted, however, that clinical complications as 
a result of aerosolized administration of aztreonam arginine 
have not been reported.
Aztreonam for inhalation is available as a single-use vial 
containing 75 mg of aztreonam and 46.7 mg of lysine. The 
lyophilized powder is to be reconstituted with 1 mL of sterile 
preservative-free diluent, and administered using the Altera® 
Nebulizer System (PARI Pharma, Midlothian, VA, USA).24 
The inhalational formulation of aztreonam has a pH range 
4.5–6.0 once reconstituted. The antimicrobial activity of 
aztreonam is not affected over a pH range 6–8, the presence 
of human serum, or reduced oxygen tensions.24,25 Aztreonam 
for inhalation should be stored refrigerated at 2°C to 8°C 
until needed; however, it is stable at room temperature for 
up to 28 days. Once reconstituted, aztreonam for inhalation 
should be used immediately.24
Microbiology
Aztreonam has potent in vitro activity against a wide spectrum 
of aerobic Gram negative organisms, including P . aeruginosa, 
Escherichia coli, Haemophilus influenzae, Proteus mirabilis, 
Citrobacter spp, Enterobacter spp, Klebsiella spp, and Ser-
ratia spp.24,25 Additionally, susceptibility to aztreonam has 
been documented for strains of P . aeruginosa recovered from 
patients with CF.28 In this study, 1240 isolates of P . aeruginosa 
were recovered from the sputum of 508 patients with CF and 
in vitro susceptibilities were determined for aztreonam and 
six other agents.28 Against this bank of isolates, the MIC50 
and MIC90 for aztreonam were 2 µg/mL and 32 µg/mL, 
respectively. Additionally, using interpretive breakpoints, 
only 11.9% of isolates were classified as being resistant to 
aztreonam. Against these same isolates, only 5.4% of isolates 
were categorized as resistant to tobramycin. It must be noted 
that application breakpoints for the treatment of pulmonary 
infections may be misleading, especially if novel routes of 
administration such as aerosolization are employed. Further-
more, comparison between agents may be skewed because 
isolates were not tested in the presence of sputum from CF 
patients. Aztreonam is much less active against Burkholderia 
cepacia and Stenotrophomonas maltophilia.29–31 Aztreonam 
does not possess activity against aerobic Gram positive 
organisms or anaerobic organisms.
In order to determine possible detrimental effects of 
nebulization on the activity of aztreonam lysinate, suscepti-
bility testing was performed with pre- and postnebulization 
aztreonam lysinate and compared with MICs determined for 
aztreonam arginate. MICs were determined for a variety of 
multidrug-resistant clinical isolates, including P . aeruginosa, 
B. cepacia complex, S. maltophilia, Achromobacter xylo-
soxidans, and Staphylococcus aureus.31 Based on attainable 
levels of aztreonam in sputum following nebulization and 
MIC distributions, the authors concluded that both salt for-
mulations of aztreonam would exhibit good activity against   
B. cepacia complex and multidrug-resistant P . aeruginosa. 
The MIC50  values  for  aztreonam  lysinate  against   
P . aeruginosa were 8 µg/mL and 4 µg/mL, pre- and postnebu-
lization, respectively. The MIC90 values against P . aeruginosa 
were 512 µg/mL and 1024 µg/mL, pre- and postnebulization, 
respectively. Against B. cepacia complex isolates, the pre- and 
postnebulization MIC50 was 32 µg/mL. Aztreonam exhibited 
little activity against S. maltophilia (MIC50  1024 µg/mL) 
and A. xylosoxidans (MIC50 = 1024 µg/mL). Comparison of 
pre- and postnebulization MICs revealed that 82% of isolates 
exhibited MICs that were either identical or within one dilu-
tion of each other pre- and postnebulization. Therefore, it was 
concluded that nebulization did not appreciably affect the in 
vitro activity of aztreonam lysinate. Furthermore, there were 
no differences with respect to the in vitro activities of the 
aztreonam lysinate and arginate salts.
The effect of sputum from patients with CF on the killing 
activity of aztreonam has also been studied. Time-kill studies 
were conducted using 1% pooled sterile sputum collected from 
patients with CF or 10% porcine gastric mucin and compared 
with controls (growth medium only).29 Kill curves were 
generated following exposure of a strain of P . aeruginosa to 
aztreonam or tobramycin at concentrations equal to 0, 0.1, 1.0, 
or 10 times the MIC. Upon inspection of time-kill data it was 
determined that the bactericidal activity of aztreonam was not 
affected by either sputum or mucin. In contrast, testing con-
ducted with tobramycin in the presence of sputum and mucin 
resulted in reduced activity, generally 2–3 log10 less killing.
Pharmacokinetics
Gibson et al conducted a multicenter, double-blind, 
placebo-controlled, dose-escalation trial to determine the Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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  pharmacokinetics and tolerability of nebulized aztreonam 
lysinate.31 Thirty-five patients with previously diagnosed CF, 
including 18 adults 18 years of age and 17 adolescents .12 
and ,18 years of age were randomized to receive a single 
dose of 75 mg, 150 mg, and 225 mg aztreonam lysinate 
on study days 0, 1, and 2, respectively, or placebo via an 
eFlow® Electronic Nebulizer (PARI Pharma). All patients 
were required to have an FEV1  40% predicted, oxygen 
saturation 90% on room air, and be clinically stable, with 
no acute upper or lower respiratory tract infection. Plasma 
and sputum samples were collected for analysis following 
nebulized administration of aztreonam or placebo.
Sputum samples were collected from patients at 10 min-
utes, two hours, and four hours postnebulization of the 
assigned study dose of aztreonam on study days 0, 1, and 2.31 
The median sputum concentrations were highest 10 minutes 
postnebulization in both the adult and adolescent groups. 
For adults, the median sputum concentrations at four hours 
postnebulization were 16 µg/g, 36 µg/g, and 52 µg/g, in the 
75 mg, 150 mg, and 225 mg aztreonam groups, respectively 
(Figure 1). In the adolescent cohort, the median sputum con-
centrations four hours postnebulization were 2 µg/g, 7 µg/g, 
and 8 µg/g, in the 75 mg, 150 mg, and 225 mg aztreonam 
groups, respectively (Figure 2). Aztreonam concentrations 
in adolescent patients were found to be consistently lower 
than those in adults. In fact, in contrast with adults, sputum 
concentrations of aztreonam in the adolescent cohort did 
not exhibit a dose-related increase at any time point. The 
authors speculated this finding to be attributable to increased 
salivary dilution in airway secretions due to milder lung dis-
ease, reduced central airway deposition of aztreonam, and 
increased lung clearance of aztreonam compared with adults. 
Based on these data, the authors concluded that aztreonam 
concentrations measured in sputum immediately following 
single doses of aztreonam lysinate generally exceed the 
aztreonam MIC90 (32 µg/mL) for P . aeruginosa by at least 
10-fold.31
Plasma pharmacokinetics of aztreonam were character-
ized following nebulized administration of a 75 mg dose 
in the adult cohort (n = 12).31 A mean maximum plasma 
concentration for aztreonam of 419 ng/mL was noted 
approximately one hour following administration of the 
nebulized dose. The mean plasma half-life was reported to 
be 2.1 hours and the mean clearance was 853 mL/minute. 
Although aztreonam was detectable for at least eight hours 
after nebulization, overall absorption and plasma exposure 
was deemed to be low.31
The elimination of aerosolized aztreonam from the 
lungs has not been well described. Unabsorbed drug may 
be eliminated through sputum expectoration. The portion of 
drug that reaches the systemic circulation undergoes minimal 
metabolism and is eliminated renally through active tubular 
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secretion and glomerular filtration, with approximately 10% 
of the dose excreted unchanged in the urine.25 The elimination 
half-life of aztreonam lysinate is approximately 2.1 hours, 
similar to that of parenteral aztreonam arginate.31
Efficacy
The efficacy of aztreonam lysine for inhalation (AZLI) in 
CF patients with stable lung function colonized/infected 
with P . aeruginosa was examined in a Phase II, random-
ized, double-blind, placebo-controlled trial.32 One hundred 
and five patients aged 13 years with diagnosed CF, FEV1 
40% predicted, oxygen saturation 90% on room air, and 
positive P . aeruginosa sputum cultures were randomized 
to receive 75 mg AZLI, 225 mg AZLI, or placebo via the 
eFlow® electronic nebulizer twice daily for 14 days. Ran-
domization was stratified by severity of disease (FEV1 40% to 
,60% or FEV1 60%). The planned primary endpoint was 
the percent change in FEV1 at day 14. Mean FEV1 reported 
at baseline was 76.2%, 74.3%, and 81.2% for the placebo, 
75 mg, and 225 mg groups, respectively, indicating relatively 
preserved lung function. At day 14, improvement in FEV1 
for patients treated with AZLI 75 mg and 225 mg did not 
differ from placebo. A post hoc analysis revealed that in a 
subgroup of patients with a baseline FEV1 , 75% predicted, 
statistically significant improvement was seen in FEV1 with 
225 mg AZLI compared with placebo at day 7 (P = 0.014). 
However, the improvement in FEV1 was not maintained 
at day 14, and the difference from placebo was no longer 
statistically significant. At follow-up 14 days from the end 
of therapy (day 28), the mean FEV1 approached baseline in 
both AZLI treatment groups.32 The change from baseline in 
P . aeruginosa sputum density measured at days 7, 14, and 28 
was also examined. P . aeruginosa sputum density increased 
from baseline in the placebo group at all three time points, 
whereas bacterial density decreased a statistically significant 
extent in both treatment groups at days 7 and 14 (Table 1). 
However, complete eradication was rare. At the end of the 
study period (day 28) the density of P . aeruginosa in the spu-
tum of AZLI-treated patients had trended back to baseline. 
Emergence of resistant isolates of P . aeruginosa over the 
course of the study was not observed.32 Factors which may 
have attributed to the failure to note a statistically significant 
improvement in lung function despite the noted change in 
bacterial density include the fact that most of the enrolled 
patients had relatively good lung function at baseline and 
the short duration of treatment and observation periods. 
One intriguing point noted was that patients treated with the 
225 mg dose of AZLI who were receiving bronchodilators 
had greater improvements in FEV1 and reductions in sputum 
P . aeruginosa density at day 14 compared with those who 
were not receiving bronchodilators. However, these differ-
ences were not maintained at day 28. It was proposed that 
bronchodilator-induced airway dilation may have facilitated 
aztreonam deposition in the lungs.32 As such, it is recom-
mended that a bronchodilator be utilized prior to nebulized 
administration of aztreonam lysine.24
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The efficacy of AZLI for suppression of P . aeruginosa 
colonization/infection was examined among a population 
of patients with CF who frequently used antibiotics for 
P . aeruginosa airway colonization/infection.33 Patients with a 
diagnosis of CF were enrolled if they were six years of age or 
older and had a current P . aeruginosa colonization/infection 
diagnosed by identification of bacteria in expectorated sputum 
or throat culture, had three or more treatment courses with 
tobramycin inhalation solution in the previous year, had an 
FEV1 25%–75% predicted, and an oxygen saturation of .90% 
on room air. On enrollment in AIR CF-2, patients were treated 
with 28 days of tobramycin inhalation solution and then 
randomized to receive AZLI 75 mg twice daily, AZLI 75 mg 
three times daily, or placebo. The primary study endpoint 
was the time required before the need for additional inhaled 
or intravenous antipseudomonal antibiotics. Secondary end-
points included change in clinical symptoms (Cystic Fibrosis 
Questionnaire-Revised [CFQ-R] respiratory score), change 
in pulmonary function, P . aeruginosa density in sputum, and 
time to hospitalization. A total of 211 patients (78% of whom 
were 18 years of age or older) completed treatment with 
tobramycin inhalation solution and entered the randomized 
phase of the study. Over the 84-day follow-up, 121 patients 
discontinued participation from the study, 76 of which met the 
primary endpoint. A total of 81 patients required additional 
antipseudomonal antibiotics, 38 in the placebo group, 19 in 
the AZLI twice daily group, and 24 in the AZLI three times 
daily group. The median time for additional antipseudomonal 
antibiotic administration was . 92 days in the AZLI twice 
daily group (P = 0.002 compared with placebo [71 days]) 
and 87 days in the AZLI three times daily group (P = 0.182). 
The median pooled (AZLI twice daily group and AZLI three 
times daily group) time to inhaled or intravenous additional 
antipseudomonal antibiotic administration was 21 days longer 
for the AZLI group than for the placebo group (92 versus 
71 days, P = 0.007). With respect to secondary endpoints, 
the adjusted mean CFQ-R respiratory scores increased by 
5.01 points in the AZLI-pooled group compared with placebo 
(95% confidence interval [CI]: 0.81–9.21; P = 0.020). Also, 
an adjusted mean improvement of 6.3% (95% CI: 2.5–10.1; 
P = 0.001) in FEV1 among the AZLI-pooled group compared 
with placebo at day 28 was noted. Furthermore, the adjusted 
mean sputum P . aeruginosa density in the AZLI pooled 
group compared with placebo at day 28 was -0.66 log10   
P . aeruginosa cfu/g (95% CI: –1.13 to –0.19, P = 0.006). 
However, time to first hospitalization and median days per 
number of patients hospitalized were not statistically different 
between study groups.33
The finding that lung function improved following 
administration of AZLI despite administration to patients 
that averaged 5.3 courses of tobramycin inhalation solution 
per year was surprising. This suggests that there may be an 
opportunity to impact pulmonary function by administering 
different antimicrobials. Future trials to study the effect of 
antibiotic cycling may be warranted. It must be noted that 
data in this trial were examined following only one cycle of 
AZLI, and that most analyses were performed at the end of 
treatment.33 Furthermore, patients in the present study had 
relatively preserved lung function at enrollment (mean FEV1 
55% predicted) and were slightly older (mean age 26 years) 
than those reported in previous studies of tobramycin inhala-
tion solution in patients with CF.33–35 These differences may 
limit the ability to make direct comparisons with respect to 
study endpoints.
Another study (AIR CF-1) evaluated the use of AZLI 
in patients with CF who were six years of age or older, had 
moderate-to-severe lung disease (FEV1 25%–75% pre-
dicted), and were colonized/infected with P . aeruginosa.36 
Patients were randomized to receive either AZLI 75 mg 
three times daily or placebo for 28 days. The primary study 
endpoint for the study was change in CFQ-R respiratory 
score. Secondary endpoints included changes in pulmonary 
function, hospitalizations, and sputum P . aeruginosa den-
sity. One hundred and sixty-four patients were enrolled in 
the study. The majority of study participants (77.4%) were 
18 years of age or older, and the mean age was 29.6 years. 
At the end of treatment on day 28 the CFQ-R respiratory 
score had increased for AZLI-treated patients and decreased 
in those in the placebo group. This difference was noted to 
be clinically and statistically significant (CFQ-R respiratory 
Table  1  Microbiologic  endpoints  following  administration  of 
aztreonam lysine for inhalation to patients with cystic fibrosis for 
14 days32
Mean change (SD) in log10 PA cfu in sputum 
from baseline
Day 7 Day 14 Day 28
Placebo +0.24 (1.31) +0.11 (0.92) +0.20 (1.07)
AZLI 75 mg  
twice daily
–1.44* (1.51) –1.46* (1.74) –0.39 (1.47)
AZLI 225 mg 
twice daily
–1.95* (1.42) –2.22* (1.92) –0.37 (1.7)
Notes: *Significant difference in change in log10 PA cfu compared with baseline   
(P , 0.001).
Abbreviations: AZLI, aztreonam lysine for inhalation; PA, Pseudomonas aeruginosa; 
cfu, colony forming units; SD, standard deviation.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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score difference of 9.7 points, P , 0.001, Table 2).36,37 
Although the difference in CFQ-R respiratory score dimin-
ished somewhat at the follow-up on day 42, scores were 
still above baseline for AZLI-treated patients, whilst scores 
among patients treated with placebo continued to decline 
(Table 2). Comparisons between patients with moderate or 
severe lung disease revealed the effects of treatment with 
AZLI to be similar. Additionally, treatment effects were 
greater in patients under 18 years of age. The adjusted mean 
FEV1 increased among AZLI-treated patients and decreased 
among those in the placebo group (day 28 treatment differ-
ence, 10.3%; 95% CI: 6.3–14.3; P , 0.001). Improvement 
in FEV1 persisted until the 14-day follow-up two weeks 
after treatment. Conversely, FEV1 continued to drop in the 
placebo group (day 42 treatment difference, 5.7%; 95% CI: 
2.1–9.4; P = 0.002). The authors did note that there was 
a modest correlation between CFQ-R respiratory scores 
and FEV1 values, thus suggesting that patient reporting of 
symptoms do not always correlate with pulmonary function. 
Adjusted mean sputum P . aeruginosa density declined in the 
AZLI treatment group with minimal change in the placebo 
group (day 28 treatment difference, -1.453 log10 cfu/g; 95% 
CI: -2.1 to -0.8; P , 0.001). Within two weeks following 
the end of treatment, density values were near baseline for 
both groups. Although there was a trend toward reduction 
in need for hospitalization among the AZLI-treated patients 
(5% versus 14% in the placebo group), this difference did 
not reach statistical significance (P = 0.064).36 In this study, 
the majority of patients were adults (mean age 29.6 years) 
and had moderate lung disease (mean FEV1 54% of 
predicted). Again, this population is older compared with 
studies reported with tobramycin inhalation solution.34,35 
Additionally, this study only looked at efficacy following 
one treatment cycle.36
Data from an open-label follow-on study (AIR CF-3) 
have been published in abstract form.38–40 According to 
data released in the abstracts, 274 patients who originally 
took part in AIR CF-1 or AIR CF-2 were continued on up 
to nine 28-day on, 28-day off cycles of AZLI. AZLI was 
administered at a dose of 75 mg twice daily or three times 
daily (as determined by the original study). Data suggest that 
improvements in disease-related endpoints (FEV1, CFQ-R 
respiratory symptom score, and sputum P . aeruginosa den-
sity) generally persist over time during on-treatment cycles. 
Patients receiving AZLI three times daily had more favor-
able results as compared with those receiving AZLI twice 
daily.38,39 However, owing to the lack of detail regarding 
study procedures, it is difficult to draw substantial conclu-
sions at this time.
Safety and tolerability
The most commonly noted adverse events in Phase II and III 
clinical trials included cough, with a possible dose-related 
trend in incidence and severity, productive cough, wheez-
ing, nasal congestion, headache, pharyngolaryngeal pain, 
pyrexia, and chest discomfort.32,33,36 Airway reactivity after 
treatment, defined as an acute decrease in FEV1 by 15% 
or more within 30 minutes of nebulization, occurred in a 
similar number of patients in the treatment groups compared 
with placebo.
Patient-focused perspectives
While factors such as antimicrobial spectrum and pharma-
cokinetic parameters are important, patient-specific factors 
and perspectives, such as quality of life, must also be taken 
into consideration when determining the most appropriate 
therapy for treating pulmonary infections in patients with CF. 
Pulmonary infections are a significant source of morbidity 
and a reason for hospitalization among patients with CF. Use 
of antimicrobial strategies to minimize these complications 
can have a positive impact on the lives of these patients. 
However, multiple courses of systemic antibiotics have been 
associated with significant systemic side effects and appre-
ciable collateral damage with respect to host flora. It has 
been these factors, as well as patient convenience, that have 
prompted clinicians to explore the use of inhaled antibiotics 
in this patient population.
Table 2 Endpoint results from the Retsch-Bogart et al trial36,37
Endpoint AZLI tid 
(n = 80)
Placebo 
(n = 84)
P value
CFQ-R respiratory scores, change from baseline (mean ± SD)
  Day 28 7.88 ± 18.88 -1.91 ± 18.64 0.0005
  Day 42 1.32 ± 18.31 -5.09 ± 17.02 0.0154
FEV1 (mean adjusted % change from baseline)
  Day 28 7.9 -2.4 ,0.0001
  Day 42 3.1 -2.6 0.0024
Log10 PA cfu in sputum (mean adjusted change from baseline)
  Day 28 -1.384 0.069 ,0.0001
  Day 42 -0.078 -0.010 NS
Required use of antipseudomonal antibiotics (% of patients)
    IV or 
additional inhaled
15.0 22.6 NS
  antibiotics
Abbreviations:  AZLI,  aztreonam  lysine  for  inhalation;  cfu,  colony-forming  units; 
CFQ-R, CF Questionnaire-Revised; FEV1, forced expiratory volume in one second; IV, 
intravenous; NS, nonsignificant; PA, Pseudomonas aeruginosa; tid, three times daily.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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When compared specifically with intravenous antibiotics, 
inhaled antibiotics provide several advantages, includ-
ing fewer invasive administration techniques, shorter 
  administration times, fewer systemic adverse drug   reactions, 
and reduced risk for administration-related infections. 
Furthermore, use of maintenance therapy with inhaled 
antibiotics may serve to help preserve pulmonary function 
among patients with CF more effectively than solely admin-
istering intravenous antibiotics in reaction to exacerbations 
of infections.
Conclusion
Use of inhaled antibiotics has long intrigued clinicians 
seeking a reliable means to deliver antimicrobials to the 
lungs. The premise has been that direct administration 
via nebulization would achieve high concentrations at 
the site of infection while minimizing systemic exposure. 
Although this approach is theoretically sound, its imple-
mentation has been fraught with problems, not the least 
of which has been the availability of drug products spe-
cifically formulated for aerosolized delivery. This barrier 
has been removed with the FDA approvals of tobramycin 
inhalation solution in 1997 and most recently aztreonam 
for inhalation in 2010, which in the US, is only available 
via a select network of specialty pharmacies. Each of these 
products was granted approval primarily as a result of data 
derived from research in patients with CF who were colo-
nized/infected with P . aeruginosa. Each of these agents 
has demonstrated efficacy in reducing bacterial burdens, 
preserving lung function, and improving symptoms asso-
ciated with disease.33,34,36,41 Interestingly, a head-to-head 
comparative study funded by Gilead Sciences is currently 
underway examining the efficacies of tobramycin inhala-
tion solution and AZLI.42
AZLI appears to be an active and safe therapeutic 
option. Studies have demonstrated a wide therapeutic 
window, with doses up to 225 mg being well tolerated.31,32 
Even at doses well below this threshold, aztreonam 
is effective in reducing bacterial loads in respiratory 
secretions.33,36 Additionally, there are data suggesting that 
aztreonam may maintain activity in the presence of spu-
tum better than tobramycin.31 AZLI 75 mg administered 
three times daily with the Altera® nebulizer system for 
28 days on, 28 days off, is currently indicated to improve 
respiratory symptoms in CF patients seven years of age 
and older with P . aeruginosa and an FEV1 25%–75% of 
predicted.24 Although approved for a wide patient subset, 
it is notable that the majority of clinical data reported to 
date have been generated in older patients with moderate 
lung disease.
Although AZLI and tobramycin inhalation solution 
are indicated for similar patient populations, it will be 
  interesting to watch how clinicians utilize these agents. One 
important question that will need to be addressed is whether 
tobramycin inhalation solution and AZLI should be used as 
mono- or combination therapy. Additionally, if combination 
therapy is employed, should the agents be used as concur-
rent or cycled inhaled combinations? Another issue that 
will require further study is emergence of resistance. Given 
that tobramycin exhibits concentration-dependent killing, 
one might argue that some resistance may be overcome by 
the delivery of higher drug concentrations to the lungs. The 
value of higher concentrations of aztreonam in the lung 
in relation to long-term emergence of resistance remains 
to be determined. Also, it needs to be further elucidated 
which patient populations are most likely to benefit from 
AZLI administration. Data published to date have primar-
ily examined patients with relatively stable and preserved 
lung function and have used exacerbation of pulmonary 
infection with P . aeruginosa as a clinical endpoint. Use in 
additional patient populations and for alternate indications 
needs to be established. It must also be remembered that no 
therapies have been shown to provide sustained eradication 
of P . aeruginosa.
One final consideration that may impact how readily 
AZLI is incorporated into clinical practice is the value added 
to patient care. The average wholesale price for a 28-day 
course of AZLI is approximately $5300, and the average 
wholesale price for a 28-day course of tobramycin inhala-
tion solution is approximately $4900, both of which are 
significantly more expensive than aztreonam arginine.43,44 It 
must then be asked whether this additional cost is justified 
in patient care. To this end, little data exist to support the 
notion that the specially formulated AZLI is significantly 
safer or more active than aztreonam arginine. However, 
the vast majority of clinical efficacy and safety data for 
nebulized administration of aztreonam to patients with CF 
have been generated using the aztreonam lysine formula-
tion. Therefore, unless data prove otherwise, it would be 
prudent to let the evidence guide therapeutic decisions and 
utilize aztreonam lysine over aztreonam arginine when 
given via inhalation.
Clinical trials, experience, and cost may ultimately dic-
tate how AZLI and other aerosolized antibiotics are used. 
However, for the time being, considerable interest exists 
regarding these agents.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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